Tweet Washington, November 5 (ANI): Cinacalcet - a drug commonly prescribed to patients with kidney failure and a disturbance of bone and mineral metabolism known as secondary hyperparathyroidism - does not significantly reduce the risk of death or major cardiovascular events, a study led by an international team of researchers has found. The results of the trial known as EVOLVE, which enrolled nearly 4,000 kidney patients from several continents and stretched over five years, were mixed, researchers said. "The results of the EVOLVE trial suggest that cinacalcet favorably alters bone and mineral metabolism, and could result in improved health and longevity for patients with end-stage renal...
0 Responses to Common drug doesn't significantly lower death risk in kidney patients